Akeso Completes Phase III Trial Enrollment of PD-1/VEGF Bispecific for NSCLC

Guangzhou Akeso completed patient enrollment in a Phase III of ivonescimab, a PD-1/VEGF bispecific antibody, compared with another PD-1, Merck’s Keytruda (pembrolizumab), as a first-line treatment for patients with PD-L1 positive advanced or metastatic non-small cell lung cancer. Akeso is currently conducting four pivotal Phase II trials of ivonescimab worldwide, including three head-to-head comparisons with PD-1 monoclonal antibodies. In late 2022, Akeso out-licensed global ex-China rights for ivonescimab to Summit Therapeutics of California in a $5 billion agreement. More details....

Stock Symbol: (HK: 9926)

Share this with colleagues: